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Abstract 
 
 
Inhibition of Bcl-2 family protein-protein interactions (PPI) is a very promising direction in 
cancer chemotherapy. Hence over the last decade, many medicinal chemistry studies 
endeavoured to discover drug candidates, and a wealth of chemical scaffolds with striking 
chemical diversity was reported as Bcl-xL inhibitors. This raises the question of whether all 
these molecules could occupy a unique binding site, or rather discrete pockets of the protein 
surface.  
To test if small and chemically diverse Bcl-xL inhibitors are likely to bind a single pocket, 
and to identify which pocket, we used a battery of computational and modeling approaches. 
We first checked that the large dataset of Bcl-xL inhibitors we built can actually fit to a 
universal pharmacophore. Then we defined the probable binding hot spots of interaction 
through comparison of crystal structures, as well as virtual fragment screening. Finally, new 
analogues of small polyphenol derivatives were synthesized to precisely probe a hydrogen 
bond suggested by docking experiments. Bcl-xL inhibition potency of these products 
confirmed the predicted binding mode. 
This combination of X-ray structure exploration, molecular modeling studies and medicinal 
chemistry supports that all these small Bcl-xL inhibitors occupy the same hot spot of 
interaction. The identification of this binding site should help the design and optimization of 
small PPI Bcl-xL inhibitors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1. Introduction 
 
Considered as exotic or as purely intellectual exercise few years ago, protein protein 
interactions (PPI) are now the subject of intensive prospecting in many biological and 
pharmaceutical projects.1 Although still considered as a very difficult field in medicinal 
chemistry, examples of PPI inhibitors have recently grown.2,3 They received significant 
attention in cancer drug discovery, because PPI are seen as signalling nodes, linking networks 
that relay oncogenic signals.4 
Members of the Bcl-2 proteins family (Bcl-2, Bcl-xL, Bcl-w, Mcl-1), which interact with 
BH3 domains, are among the most studied protein targets in that area. They have indeed 
critical implication in apoptosis and cell proliferation pathways, and Bcl-xL is considered as a 
robust biomarker for some cancers.5,6 Drug candidates emerged from these investigations, and 
the Bcl-2 family inhibitor Navitoclax for example, is currently evaluated in phase 2 clinical 
trials.7 Moreover, a large scale genomic analysis showed that Bcl-xL mRNA and protein 
levels were associated with drug sensitivity of proliferating cells, suggesting that Bcl-xL 
could be implicated in resistance to chemotherapies.8 Hence Navitoclax potentiates the 
activity of chemotherapeutic regimens.9  
Many Bcl-xL inhibitors covered by a wealth of molecular scaffolds have been described in 
recent years.10 The chemical diversity of published molecules is actually striking, from 
peptides to small drug-like molecules. Inhibition of Bcl-xL and BH3-domains interaction 
were first obtained with BH3-mimetics.11,12,13,14,15 Then chemically-modified peptides were 
described, such as stabilized alpha-helix of Bcl-2 domain (SAHBs).16,17 Due to the limited 
pharmaceutical potential of peptides, small molecule inhibitors were avidly sought. This led 
to the discovery of natural molecules, polyphenols or alkaloids,18,19 and many synthetic 
analogs (Fig. 1). More recently, fragment-based drug design approaches were used to 
circumvent the synthetic complexity of natural products.20,21 So different classes of molecules 
show little similarity, and question the nature of their binding site. Do these different ligands 
bind to discrete subcavities of Bcl-xL protein surface, or do they share a common and unique 
binding site? 
The binding site of some inhibitors has been unequivocally identified by experimental studies, 
using X-ray or NMR structure solving. Unfortunately, these studies were undertaken with 
large molecules, without clear similarity with smaller ligands such as natural products.22 Co-
crystallized large molecules occupy different subsites of the BH3 groove. Only portions of 
inhibitors overlap (Fig. 1), which makes difficult the definition of a shared protein interface, if 
any.  
 
 
Fig. 1 Superimposition of co-crystallized inhibitors of Bcl-xL.22 
 
One can suppose that these wide-ranging protein-ligand contacts are not mandatory. It is 
known actually that only fraction of ligands is responsible for their affinity, and interaction 
  
energy lies essentially on so-called hot spot of binding.23,24 Not all chemical groups of a 
ligand participate in the binding energy, or not in a linear and additive mode, giving rise to the 
concept of ligand efficiency (LE).25  
It is probable that small Bcl-xL inhibitors occupy the hot spots of binding, explaining their 
high affinity compared with their limited size. To conceive smaller Bcl-xL inhibitors, with 
higher LE than current molecules, it is thus decisive to know what part of the large molecules 
makes a significant contribution to the binding energy, and in which protein pocket(s) the 
binding hot spots are located. 
This work intends to answer two interwoven questions: first, is there a unique binding site for 
small size Bcl-xL inhibitors? Secondly, is it possible to identify hot spot(s) of binding for 
known inhibitors? We tackled these questions by using a combination of crystal structure 
analysis, molecular modeling experiments and hypothese validation through novel 
compounds synthesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
2. Results and Discussion 
 
2.1 Is a unique binding site possible? Building of a pharmacophore model 
 
A good way to address the first question is to test if molecular scaffolds of small Bcl-xL 
inhibitors can fit to a unique pharmacophore model. We used a compilation of known 
inhibitors with wide chemical diversity to build hypotheses (Fig.2).  
 
name structure Ki 
$ reference name structure Ki 
$ reference
(nM) (nM)
19-93 930 29 TM-179 1100 32
BCL-LZH-040 17 30 TW-37 1100 53
BH3I-1 2400 26 wei2 2018 34
BH3-I2 4100 26 wei6a 344 34
BI21-C6 500 28 wei6c 1636 34
biflavonoid 1200 32 wei6d 6900 34
DCBL55 3400 27 wei6e 982 34
flavonoid 1780 32 wei6i 185 34
gossypol 1000 33 wei7 185 34
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Fig. 2 Reference Bcl-xL PPI inhibitors used to build the pharmacophore model. $ If Ki was 
not available, IC50 is reported instead.26,27,28,29,30,31,32,33,34 
 
Using automatic pharmacophore generation and further refinements of the hypotheses, a five-
feature pharmacophore can actually be defined using this dataset. The model can be described 
as a four-branched star. Three branches are constituted by three hydrogen bond (HB) vectors 
originating from the centre of the star, the last branch being drawn by two hydrophobic 
spheres, slightly out of the plane (Fig. 3A). A distance of 3.3 Å is measured between the 
lipophilic spheres, and 6.5 Å between the centroid of HB vectors and the first lipophilic 
sphere. As examples, Fig. 3B shows different scaffolds conformed to the pharmacophore. 
This model is close to a previously decribed pharmacophore based on peptide ligands of Bcl-
xL.35 In this four feature pharmacophore (2 HB and 2 hydrophobic groups), a distance of 
about 5 Å can be estimated for d1, and 6 Å for d2. 
  
  
 
Fig. 3A Pharmacophore of Bcl-xL PPI inhibitors built using the Fig. 2 dataset, viewed from 
above the plane (left) and in profile (right). Lipophilic features are represented by blue 
spheres, HB acceptor by green vectors. d1 = 3.3 Å, d2 = 6.5 Å 
Fig. 3B Example of Bcl-xL inhibitors superimposed to the pharmacophore. From left to right, 
and up to down: TM-179, 19-93, wei6i, BI21-C6 (Fig. 2)                          . 
  
 
   
 
 
If all inhibitors had not been able to match the pharmacophore, we would have concluded that 
they bind to different sites of the protein surface, each molecular scaffold having its own 
cavity. Here, even if we can’t be definitely assertive, the ability of all ligands to define a 
unique pharmacophore argues in favour of the one-site hypothesis. 
 
 
2.2 Identification of binding hot spots with co-crystallized Bcl-xL complexes. 
 
To test if the above conclusion is compatible with available Bcl-xL protein structures, we 
turned towards structure-based information, and we complemented these observations with 
molecular modelling experiments. 
  
By superimposing experimental 3D structures of Bcl-xL, we observed 2 hydrophobic cavities 
that accommodate lipophilic amino acids conserved among peptide-Bcl-xL complexes (Fig. 
4). These clusters are formed by one hydrophobic amino acid per helix turn, with a mean 
pitch of 6.2 Å (cluster 1) and 7.5 Å (cluster 2). Peptide cluster 1 is surrounded by Bcl-xL 
residues Leu108, Leu111, Phe97, Phe105, Leu130 and Phe146. Cluster 2 is lined with Ala93, 
Tyr101, Val141 and Phe191. Flanked by the clusters, a triad basic-hydrophobic-acid is also 
conserved. The basic residue (usually Arg) form a salt bridge with Glu129 of Bcl-xL, and the 
acidic Asp with Arg139. Bak peptide lacks the basic residue (Ala instead), Soul peptide has 
no acidic amino acid, and they don’t form any compensating salt bridge. So it is tempting to 
see the conserved clusters of hydrophobic amino acids and the corresponding cavities in Bcl-
xL as the main binding hot spots. This is in agreement with previous free energy 
decomposition analysis, showing that these hydrophobic residues are crucial for peptides 
interaction.36 
 
 
1BXL (hBak)     --------GQVGRQLAIIGDDINR------------ 
1G5J (hBad)     ---NLWAAQRYGRELRRMSDEFVDSFKK-------- 
2BZW (mBad)     APPNLWAAQRYGRELRRMSDEFEGSFK--------- 
3FDL (hBim)     ----MRPEIWIAQELRRIGDEFNAYYARR------- 
1PQ1 (mBim)     ---DLRPEIRIAQELRRIGDEFNETYTRRVFANDYR 
2P1L (hBeclin)  ---GSGTMENLSRRLKVTGDLFDIMSG--------- 
3R85 (hSoul)    -----EQLLTLASILREDGKVFDEK----------- 
                              ______       ______  
            cluster 1 triad cluster 2 
 
Fig. 4  Superimposition of BH3 peptides bound and co-crystallized with Bcl-xL. The 
sequence alignment is based on Bcl-xL protein structure superposition. Two hydrophobic 
clusters appear, separated by a nearly conserved triad Arg-Hydrophobic-Asp.  
 
 
The first Bcl-xL small molecule complex was obtained by fragments library co-
crystallisation.20 Two mostly hydrophobic fragments were found to occupy pockets lined with 
Leu108, Ala114, Phe115 and Leu130 (called site 1 in the seminal study20), and Ala142, 
Arg165, Tyr195 (called site2). Site 1 corresponds to a region encompassing the second 
hydrophobic residue of the above triad and cluster 1, site 2 corresponds to cluster 2. Hence 
comparison of peptides and fragments crystal structures supports strongly that site 1 and site 2 
constitute binding hot spot for Bcl-xL.  
 
  
 
2.3 Identification of binding hot spots by virtual fragment screening. 
 
The importance of sites 1 and 2 was confirmed by virtual fragment screening. Indeed, there is 
substantial evidence that hot spots may be characterized by their ability to bind a variety of 
small molecules such as solvents, and that hot spots can be reliably determined by 
computational means.37,38 Methane and cyclohexane probes screened on the complete protein 
surface clustered actually on these 2 cavities (Fig. 5). Site 2 is more populated by cyclohexane 
than site 1, and binding energy calculations suggest that site 2 could be the most important hot 
spot. Conversely,39 water probes were excluded from these cavities (Table 1). 
 
  
  
 
Fig. 5  Multiple Copy Simultaneous Search (MCSS)40 with hydrophobic fragments on Bcl-xL 
protein surface. Cyclohexane clustered on site 1 and site 2 (left), as well as methane probe 
(right). Co-crystallized fragments20 are in yellow. 
 
  
probe rank site fragment Binding Energy
(kcal / mol)
Methane 1 2 -28,3
8 1 -19,5
9 1 -18,5
10 1 -17,9
Cyclohexane 1 2 -34,7
18 1 -24,1
20 1 -21,5
Water 60 2 -0,86
141 2 2,24
17 1 -4,31
123 1 1,51
203 1 7,95
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Table 1  Description of hydrophobic probes binding by MCSS.40 Bold atoms and bonds of the 
original co-crystallized fragments indicates probe subcavity occupancy. 
 
Having determined two binding hot spots, the precise binding mode of small ligands remains 
to be solved. To this end, we used one of the most efficient scaffold among the series of Bcl-
xL inhibitors, i.e. polyphenol derivatives. Fragment deconstruction41,42 of compound 6 ref43 
deciphered the most probable binding sites for polyphenol (Fig. 6, table 2). The polyphenol 
(fragment A) clustered in three subregions of site 2. The first (Site 2a) is sandwiched between 
Asp95 and Tyr195, above Ala93. The second (site 2b) corresponds to the subcavity occupied 
by the cyclohexyl of crystallized tetrahydronaphtalen-1-ol, above Val141. The third  (site 2c) 
is between the others, overhung by Glu96, Arg100 and Tyr101. Fragment B and C are centred 
on the latter region, suggesting it could be actually the polyphenol biding site. This region 
form a hinge between the hydrophobic hot spots, ideally placed to link two hydrophobic 
groups of ligands.  
 
 
   
  
 
 
  
 
Fig. 6  Virtual fragment screening by decomposition of compound 6 ref43 in Bcl-xL protein surface. 
Polyphenol fragment A clustered in three subpockets of site 2 (top, sites 2a to 2c from left to right). At 
the bottom, fragments B and C occupied the median subpocket. Co-crystallized fragments20 are in 
yellow. 
 
site subcavity fragment fragment Binding Energy
structure name (kcal / mol)
Compound 6 ref
2 a A -14,6
2 b A -7,8
2 c A -10,9
2 c B -19,3
2 c C -27
1 a D -28
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Table 2  Fragment deconstruction of compound 6.43 Binding energy was calculated after MCSS. 
 
Accordingly, classical docking and scoring showed this region can accommodate potent 
inhibitors, as illustrated by TM-179,43 a bulkier analog of compound 6 ref with two large 
hydrophobic groups (Fig. 7). In this binding mode, the polyphenol forms HB with Glu96 and 
Arg100, the diphenyl ether occupies roughly the site 2, and the benzothiazole group turns 
onto the site 1, near Trp137. MCSS confirmed that site 2 was among the preferred crevices 
for diphenyl ether fragment D (table 2). 
  
 
 
Fig. 7  Proposed binding mode of TM-179 (Fig. 2), superimposed with co-crystallized 
fragments in yellow. 
 
 
2.4 Testing the predicted binding mode with novel compounds: synthesis of ketone 
bioisosters 
 
Interestingly, the ketone of the benzothiazole face is well-positioned to form an HB with 
Tyr101, and we previously suggested that the ketone of a para-fluorobenzyl derivative of 
compound 6 ref form such a HB.44 The triazole series we described recently, including the 
mixed polyphenol-triazoles A and B (Fig. 8), conserved the HB ability.45 However, minute 
changes of the ligand positioning in the binding site was supposed to impair the interaction.46 
So we tested in the present work bioisosteric replacements to probe subtle variations of the 
HB vector geometry.47 These new compounds, pyrimidine 1 and phthalazine 2 were prepared 
and submitted to Bioluminescence Resonance Energy Transfer (BRET) assay. 
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Fig. 8  Novel compounds 1 and 2 based on previous lead A and B. 
 
The synthesis of the desired pyrimidine 1 is reported in Scheme 1. Metallation by n-Buli of 
commercially available alkyne 3, followed by addition on aldehyde 4,42 gave the 
corresponding propargylic alcohol which was immediately oxidized with IBX to afford the 
  
propargylic ketone 5 in 69 % overall yield for the two steps. Then, condensation of 5 with 
amidine gave the pyrimidine 6 in 72% yield. Finally, BBr3-mediated deprotection of the 
methoxy ethers afforded the target pyrimidine 1 in 61% yield. 
 
 
Scheme 1  Synthesis of the mixed polyphenol-pyrimidine inhibitor 1.  
 
The synthesis of the designed phtalazine 2 is reported in Scheme 2. Metallation of known47 
bromide 7 followed by reaction with DMF gave the aldehyde 8 in 43% yield. Then, reaction 
with phenol afforded the ether 9 in 81% yield. Reaction with the lithium derivative of 13,40 
gave the benzylic alcohol 10 (67%) which was oxidized and deprotected to give the keto-
aldehyde 11 (91% for two steps). Condensation with hydrazine gave in 72% yield the 
phthalazine 12 and after deprotection of the ether groups the target molecule 2 (80% yield). 
 
 
 
 
Scheme 2  Synthesis of the mixed polyphenol-phthalazine inhibitor 2.  
 
  
 
 
BRET assay and immunoprecipitation support a strong interaction of the compounds with 
Bcl-xL (Fig. 9). The pyrimidine 1 proved to be slightly better than reference compound 6 ref 
while the phthalazine derivative 2 showed activity equivalent to ABT-737. Thus biological 
results outline the importance of a HB acceptor in appropriate position and confirm the 
predicted binding mode (Fig.10). 
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Fig. 9A (left) BRET activity of reference and novel compounds.  
9B (right) Representative immunoprecipitation experiment assessing inhibition of Bax-Bcl-xL 
interaction by the small molecules. Protein complexes were immunoprecipitated from cell 
extracts with anti-Bcl-xL antibody. Anti-Bax was used in line 1, anti-Bcl-xL in line 2. A 
nonspecific band (actin) was used to estimate protein loading. 
 
 
  
 
Fig. 10 Proposed binding mode of the novel aromatic bioisosters. Tyr101 forming an HB with 
the pyridazine and pyrimidine  is detailed in thin sticks. 
 
 
 
Finally, we paralleled our ligand-based model to the structural analyses. Manual docking of 
our pharmacophore in the Bcl-xL surface shows that ligand-based and structure-based models 
are convergent: if hydrophobic spheres of the pharmacophore occupy the site 2, HB partners 
can be found at the expected position:  Glu96 and Arg100 for the polyphenol, Tyr195 and 
Arg100 / Tyr101 for the two ketones (Fig. 11). 
 
  
 
 
Fig. 11  Manual docking of the pharmacophore model , superimposed with two poses of TM-
179 obtained by classical docking, in head-to-tail orientation (left and right). 
 
3. Conclusion 
 
Prosurvival Bcl-2 family of proteins is a mainspring of cell survival and apoptosis pathways, 
repressing cell death by inhibiting proapoptotic effectors such as Bax, Bak or BH3-only 
proteins. It is consequently the subject matter of many drug discovery efforts in anticancer 
therapy. However, PPI is a challenging task for drug-like molecules, because of the 
characteristics of the protein interfaces: they are usually flat or less concave than classical 
drug binding sites, and have a larger surface area.48 At the periphery of proteins and solvent-
exposed, interfaces are less subject to structural constraints, and Bcl-xL proved to be 
particularly flexible.49,50 Transient pocket may also form on these surfaces.51 Structural 
studies with Bcl-xL have shown that PPI inhibitors bind the large crevice receiving BH3 
peptides, acting as competitive inhibitors.20,52 They revealed also that large molecules occupy 
different subcavities of the crevice. Only portions of inhibitors overlap, making precise 
identification of small molecules binding site difficult. 
If recent medicinal chemistry efforts allowed Bcl-xL PPI inhibitors affinity to increase, their 
size has grown simultaneously, moving them away from ideal drug candidates. To impede 
this evolution, we decided to go back to small efficient scaffolds, illustrated by polyphenol 
derivatives. Previous studies showed that polyphenols bind to the large BH3 interface, and 
molecular modelling with Bcl-2 suggested that they occupy a subcavity formed by Leu130, 
Leu108, Phe146, Phe107 and Tyr195. Polyphenols were supposed to make HB with Arg139 
and Asn136.53  
By using a combination of structural comparisons, structure-based and ligand-based 
molecular modelling experiments as well as structure-activity relationship analysis, the 
present work supports another binding site. The difference in the hypothetical binding site for 
polyphenol compounds results certainly from the available crystal structures, i.e. protein 
conformation considered. Wang et al. made their assumption based on a homology model of 
Bcl-2 built on Bcl-xL co-crystallized with Bim peptide.53,43 Since additional 3D structures are 
now available, we analyzed this experimental conformational ensemble of Bcl-xL protein, 
and we compared the binding modes of co-crystallized ligands. Despite that ABT-737 and 
more recent inhibitors occupy actually the middle of the BH3 binding groove, our analysis 
supports the possibility that smaller inhibitors have greater ligand efficiency by making use of 
binding hot spots. Site 1 and 2 detected by fragment crystallization are certainly these hot 
spots, and a hinge between them is more amenable to bind polyphenol derivatives than 
previously proposed pocket. This novel site still belongs to the Bak crevice, but its centroid is 
around 12 Å away from previously suggested cavity of the paralog Bcl-2 protein. 
This revised binding site will be used in further studies to explore the polyphenol chemical 
space, and should be useful in the design of more efficient small molecule inhibitors. 
  
4. Materials and Methods 
 
4.1 Pharmacophore generation 
 
The pharmacophore model was obtained using auto pharmacophore generation procedure 
implemented in Discovery Studio 4.0 (Accelrys Inc. San Diego, CA). A maximum of 6 
features were allowed, with a minimum interfeature distance of 2 Å. Among the 20 
hypotheses generated, we selected the model permitting the best consensus between number 
of matching features and fitting value. A ligand pharmacophore mapping with flexible fitting 
method was used thereafter to refine ligands superimposition, each molecule conformation 
being considered separately. 
 
4.2 MCSS and binding energy calculation 
 
Multiple Copy Simultaneous Search (MCSS)40 was carried out twice, with a concentric search 
for the binding sites and an increasing precision. First, the procedure was driven on the entire 
protein surface of PDB: 1YSG.20 The explored ‘binding sites’ encompassed all the protein 
structure, with a sphere radius of 27 Å. 1000 fragment replicas were initially placed in the 
receptor cavities, and poses were optimized by 10000 steps of Powel minimization, following 
8000 steps of steepest descent, using CHARMm force-field.  
Binding free energy was calculated using a molecular mechanics Poisson-Boltzmann with a 
non polar surface area implicit solvent model (MM-PBSA), as described with MM-GBSA.54 
Cyclohexane probes clustered in different subregions of the protein surface, with a wide range 
of binding energy (BE of -14.2 to 31.3 kcal/mol). The first 3 poses of cyclohexane probe 
occupied the site 2. Due to its smaller size, methane probe occupied more diffuse and discrete 
clefts (BE from -13.4 to 18.6 kcal/mol). The third poses occupied site 1 (BE = -11.6 
kcal/mol). Water probe was also diffuse (BE from -11.2 to 15.1 kcal/mol). The 123rd pose 
occupied site 1 (BE = 1.5 kcal/mol), as well as the 160 th pose (BE = 3.88 kcal/mol). The 
former corresponds to the crystallized fragment fluorophenyl subpocket, the later to the 
benzoic acid part. The 141st pose occupied site 2 (BE = 2.3 kcal/mol). 
Due to the cyclohexyl clustering, a second MCSS step was performed. This step focused on a 
region including site 1 and site 2 (sphere radius of 13 Å), allowing more detailed protein-
probes interaction analysis. This refinement procedure produced results given in Table 1 and 
2. 
 
4.3 Classical Docking 
 
Docking experiments from crystal structure (PDB:1YSG) were performed using LigandFit, 
implemented in Discovery Studio v.4.0. A CFF energy grid was defined with 10 Å extension 
from the binding site of 1134 Å3, and an energetic penalty of 150 kcal/mol/atom was set 
outside the binding site. A softened potential energy was used, with distance dependant 
dielectric constant of 1. 
Ligands conformers were generated before docking experiments by using both “fast” and 
“best” protocols, i.e. discretized rotations about the rotatable bonds with 120° search 
increments between sp3 atoms, with and without energy minimization steps. 
After docking, each pose and binding site (ligand-receptor complex) were optimized through 
energy minimization (6000 steps of steepest descent with CHARMm force field). 
 
 
 
  
 
4.4 Chemical syntheses 
 
 4.4.1 preparation of 1-(5-(4-fluorobenzyl)-2,3,4-trimethoxyphenyl)-3-(4-
phenoxyphenyl)prop-2-yn-1-one (5) 
 - first step: to a solution of propargyl derivative 3 (411 mg, 2.12 mmol) in THF (10 
ml) at -78°C under argon, was added dropwise n-BuLi (1.65 ml, 1.25 eq., 1.6 M in pentane). 
The mixture was stirred for 30 minutes. Then, a solution of aldehyde 4 (608 mg, 1 eq.) in 
THF (3 ml) was added, at -78°C, to this organolithium derivative. The reaction mixture was 
allowed to warm up slowly to rt and it was stirred overnight and then quenched with a 
saturated ammonium chloride solution. The mixture was extracted with Et2O. The combined 
organic layers were dried over MgSO4 and concentrated under reduced pressure to give the 
crude product that was used as such for the next step. 
 
 - second step: a solution of previous alcohol crude product (< 2.12 mmol), IBX (890 
mg, 1.5 eq.) in a 4/1 mixture of THF/DMSO (25 ml) was heated under reflux for 20 minutes. 
After cooling down to rt, the reaction mixture was poured into water and filtered on celite. 
The solution was then extracted with Et2O, washed with water and brine. The combined 
organic layer was dried over MgSO4 and concentrated under reduced pressure. The crude 
product was purified on a silica gel column using a 7/3 mixture of pentane/ether as eluent to 
afford 5 (705 mg, 69%, 2 steps) as an orange solid.   
 
 1H NMR (300 MHz, CDCl3) δ (ppm): 7.57 (s, 1H), 7.53 (d, J = 8.8 Hz, 2H), 7.22-7.14 (m, 
3H), 7.09-7.04 (m, 2H), 7.01-6.93 (m, 4H), 4.00 (s, 3H), 3.92 (s, 2H), 3.90 (s, 3H), 3.85 (s, 
3H). 13C NMR (75 MHz, CDCl3) δ (ppm): 175.6, 161.4 (d, J = 244.2 Hz), 159.9, 156.7, 
155.5, 154.2, 146.4, 136.0 (d, J = 3.2 Hz), 134.9, 130.3 (d, J = 7.8 Hz), 130.0, 127.3, 126.8, 
124.5, 120.0, 118.0, 115.2 (d, J = 21.2 Hz), 114.5, 91.6, 89.2, 61.8, 60.9, 60.8, 35.3. 19F NMR 
(282.4 MHz, CDCl3) δ (ppm): −117.1. HRMS (ESI
+): C31H25FO5Na [M + Na]
+ m/z; calc: 
519.1584, found: 519.1590.  
 
 
 4.4.2 preparation of 4-(5-(4-fluorobenzyl)-2,3,4-trimethoxyphenyl)-6-(4-
 phenoxyphenyl)pyrimidine (6) 
 
To a solution of propargylic ketone 5 (200 mg, 0.3 mmol) in CH3CN (15 ml) were added 
sodium carbonate (513 mg, 12 eq.) and formamidine acetate (378 mg, 6 eq.). The solution 
was stirred under reflux overnight. After cooling down to rt, the mixture was filtered and 
concentrated in vacuo. The product was purified on a silica gel column with a 8/2 mixture of 
pentane/AcOEt as eluent to afford pyrimidine 6 (157 mg, 72%) as a yellow viscous oil. 1H 
NMR (300 MHz, CDCl3) δ (ppm): 9.27 (d, J = 1.5 Hz, 1H), 8.29 (d, J = 1.5 Hz, 1H), 8.12 (d, 
J = 8.7 Hz, 2H), 7.58 (s, 1H), 7.40 (dd, J = 7.5, J = 8.4 Hz, 2H), 7.23-7.08 (m, 8H), 6.96 (t, J 
= 8.9 Hz, 2H), 3.97 (s, 3H), 3.96 (s, 2H), 3.84 (s, 3H), 3.79 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ (ppm): 163.1, 162.8, 161.3 (d, J = 243.7 Hz), 160.0, 158.8, 156.1, 153.9, 151.9, 
146.6, 136.5 (d, J = 3.2 Hz), 131.6, 130.7, 130.1 (d, J = 7.8 Hz), 129.9, 128.8, 126.5, 126.0, 
124.0, 119.6, 118.4, 116.3, 115.0 (d, J = 21.2 Hz), 61.4, 60.8, 60.7, 35.5. 19F NMR (282.4  
MHz, CDCl3) δ (ppm): −117.4. HRMS (ESI
+): C32H28FN2O4 [M + H]
+ m/z; calc: 523.2033, 
found: 523.2031.  
 
 4.4.3 preparation of 4-(4-fluorobenzyl)-6-(6-(4-phenoxyphenyl)pyrimidin-4-
yl)benzene-1,2,3-triol (1)  
  
 
To a stirred solution of compound 6 (157 mg, 0.3 mmol) was added dropwise BBr3 (3 ml, 10 
eq., 1M in CH2Cl2) in CH2Cl2 (5 ml) at -78°C under nitrogen. The reaction mixture was 
allowed to warm up to rt and stirred overnight. The mixture was quenched with MeOH. After 
evaporation of the solvent to dryness, the residue was recrystallized from CHCl3 to afford 1 
(88 mg, 61%) as an orange solid. Mp: 205-207°C. 1H NMR (300 MHz, DMSO d6) δ (ppm): 
13.92 (br s, 1H), 9.29 (br s, 1H), 9.12 (s, 1H), 8.82 (br s, 1H), 8.51 (s, 1H), 8.38 (d, J = 8.9 
Hz, 2H), 7.84 (s, 1H), 7.46 (dd, J = 7.6, 8.3 Hz, 2H), 7.28 (dd, J = 5.7, 8.6 Hz, 2H), 7.22 (tt, J 
= 1.1, 7.4 Hz, 2H), 7.16-7.11 (m, 4H), 7.05 (t, J = 8.9 Hz, 2H), 3.89 (s, 2H). 13C NMR (75 
MHz, DMSO d6) δ (ppm): 164.6, 160.5 (d, J = 244.0 Hz), 160.4, 159.7, 158.8, 156.0, 155.6, 
149.2, 148.2, 137.7 (d, J = 3.2 Hz), 132.9, 130.9, 130.2, 130.0 (d, J = 7.8 Hz), 129.4, 124.3, 
119.7, 118.0, 114.6 (d, J = 21.2 Hz), 109.6, 108.6, 34.6. 19F NMR (282.4 MHz, DMSO d6) δ 
(ppm): −118.0. HRMS (ESI+): C29H21FN2O4Na [M + Na]
+ m/z; calc: 454.9270, found: 
454.9268.  
 
 
 4.4.4 preparation of 2-(1,3-dioxan-2-yl)-4-fluorobenzaldehyde (8) 
 
To a solution of 7 (510 mg, 2 mmol) in Et2O (10 ml) was added dropwise under argon, n-
BuLi (1.56 ml, 1.25 eq.) at -78°C. The mixture was stirred for 30 minutes at -78°C before 
addition of DMF (0.3 ml, 2 eq.). The reaction mixture was allowed to warm up to rt and 
stirred for 4h and then quenched with a saturated ammonium chloride solution and extracted 
with Et2O. The combined organic layers were dried over MgSO4 and concentrated under 
reduced pressure. The crude product was purified by flash column chromatography using a 
7/3 mixture of pentane/Et2O as eluent to afford aldehyde 8 (174.6 mg, 43%) as a colorless oil. 
1H NMR (300 MHz, Acetone D6) δ (ppm): 10.30 (s, 1H), 7.98 (dd, J = 5.7, 8.4 Hz, 1H), 7.44 
(dd, J = 2.4,  9.6 Hz, 1H), 7.34-7.28 (m, 1H), 6.13 (s, 1H), 4.27-4.21 (m, 2H), 4.14-4.05 (m, 
2H), 2.24-2.05 (m, 1H), 1.57-1.48 (m, 1H). 13C NMR (100 MHz, Acetone D6) δ (ppm): 191.8, 
167.3 (d, J = 252.9 Hz), 145.6 (d, J = 8.7 Hz), 133.4 (d, J = 9.6 Hz), 117.7 (d, J = 22.0 Hz), 
115.9 (d, J = 23.9 Hz), 100.3 (d, J = 1.6 Hz), 69.2, 27.5. 19F NMR (282.4 MHz, CDCl3) δ 
(ppm): −106.2. HRMS (ESI+): C11H11FO3Na [M + Na]
+ m/z; calc: 233.0590, found: 233.0591. 
 
 4.4.5 preparation of 2-(1,3-dioxan-2-yl)-4-phenoxybenzaldehyde (9) 
 
A solution of aldehyde 8 (157.6 mg, 0.77 mmol), phenol (75.9 mg, 1.05 eq.) and K2CO3 
(212.5 mg, 2 eq.) in DMF (5 ml) was heated at 110°C overnight. After cooling down to rt, 
water was added. The mixture was extracted with Et2O, washed 2-3 times with water and 
brine. The combined organic layers were dried over MgSO4 and concentrated under reduced 
pressure. The crude product was purified by flash column chromatography using a 7/3 
mixture of pentane/Et2O as eluent to afford the desired product 9 (173.4 mg, 81%) as a 
colorless oil. 1H NMR (300 MHz, CDCl3) δ (ppm): 10.37 (s, 1H), 7.89 (d, J = 8.7 Hz, 1H), 
7.40 (t, J = 7.6 Hz, 2H), 7.30 (d, J = 2.4 Hz, 1H), 7.21 (td, J = 1.1, 7.4 Hz, 1H), 7.06 (d, J = 
7.8 Hz, 1H), 6.98 (dd, J = 2.4,  8.7 Hz, 1H), 6.00 (s, 1H), 4.30-4.24 (m, 2H), 4.02-3.97 (m, 
2H), 2.28-2.18 (m, 1H), 1.49-1.43 (m, 1H). 13C NMR (75 MHz, CDCl3) δ (ppm): 190.7, 
162.3, 155.1, 142.2, 132.6, 130.1, 128.4, 124.7, 120.3, 111.4, 116.2, 93.3, 67.6, 25.6.  HRMS 
(ESI+): C17H16O4Na [M + Na]
+ m/z; calc: 307.0946, found: 307.0940.  
 
 4.4.6 preparation of (2-(1,3-dioxan-2-yl)-4-phenoxyphenyl)(5-(4-fluorobenzyl)-
2,3,4-trimethoxyphenyl)methanol (10)  
 
  
To a solution of bromo derivative 13,47 (230 mg, 0.65 mmol) in Et2O (5 ml) was added 
dropwise under argon, t-BuLi (0.89 ml, 2.2 eq.) at -78°C. The mixture was stirred for 30 
minutes at -78°C before addition of a solution of aldehyde 9 (150 mg, 0.83 eq.) in Et2O (2 
ml). The reaction mixture was allowed to warm up to rt and stirred overnight and then 
quenched with a saturated ammonium chloride solution and extracted with ethyl acetate. The 
combined organic layers were dried over MgSO4 and concentrated under reduced pressure. 
The crude product was purified by flash column chromatography using a 7/3 mixture of 
pentane/EA as eluent to afford the alcohol 10 (199 mg, 67%) as a colorless viscous oil. 1H 
NMR (300 MHz, Acetone D6) δ (ppm): 7.41-7.33 (m, 3H), 7.28-7.21 (m, 3H), 7.12 (tt, J = 
1.1, 7.4 Hz, 1H), 7.10 (s, 1H), 7.02 (t, J = 8.9 Hz, 2H), 6.99-6.96 (m, 2H), 6.93 (dd, J = 2.7, 
8.5 Hz, 1H), 6.33 (d, J = 4.3 Hz, 1H), 5.76 (s, 1H), 4.40 (d, J = 4.4 Hz, 1H), 4.17-3.79 (m, 
4H), 3.92 (s, 2H), 3.84 (s, 3H), 3.73 (s, 3H), 3.62 (s, 3H), 2.12-1.98 (m, 1H), 1.44-1.36 (m, 
1H). 13C NMR (75 MHz, Acetone D6) δ (ppm): 163.1 (d, J = 241.7 Hz), 159.4, 157.7, 152.8, 
151.5, 148.0, 140.0, 139.7, 139.5 (d, J = 3.3 Hz), 134.6, 132.2 (d, J = 7.9 Hz), 131.7, 131.1, 
130.8, 125.2, 125.0, 120.4, 118.3, 116.6 (d, J = 21.3 Hz), 100.4, 69.0, 68.9, 67.6, 61.9, 61.8, 
61.7, 36.8, 27.5. 19F NMR (282.4 MHz, Acetone D6) δ (ppm): −119.3. HRMS (ESI
+): 
C33H33FO7Na [M + Na]
+ m/z; calc: 583.2108, found: 583.2105.  
 
  4.4.7 preparation of 2-(5-(4-fluorobenzyl)-2,3,4-trimethoxybenzoyl)-5-
phenoxybenzaldehyde (11) 
 
First, a solution of previous alcohol 10 (187 mg, 0.33 mmol), IBX (140.2 mg, 1.5 eq.) in a 4/1 
mixture of THF/DMSO (5 ml) was heated under reflux for 20 minutes. After cooling down to 
rt, the mixture was poured into water and filtered on celite. The solution was then extracted 
with Et2O, washed with water and brine. The combined organic layer was dried over MgSO4 
and concentrated under reduced pressure. This crude product (pure by NMR) was used 
directly for next step. Then, to a solution of this ketone (< 0.33 mmol), 10% HCl (0.44 ml) in 
a 2/1 mixture of THF/H2O (9 ml), was heated at 80°C overnight. After cooling down to rt, the 
solution was neutralized with a saturated sodium bicarbonate solution and extracted with 
Et2O. The combined organic layers were dried over MgSO4 and concentrated under reduced 
pressure. The residue was purified on a silica gel column using the mixture pentane/ether 7/3 
as eluent to give 11 (151.3 mg, 91%, 2 steps) as a light yellow viscous oil. 1H NMR (300 
MHz, CDCl3) δ (ppm): 10.18 (s, 1H), 7.51 (d, J = 2.6 Hz, 1H), 7.46 (d, J = 8.5 Hz, 1H), 7.41 
(dd, J = 7.5, 8.4 Hz, 2H), 7.22 (tt, J = 1.1, 7.4 Hz, 2H), 7.18-7.13 (m, 4H), 7.09-7.05 (m, 2H), 
6.96 (t, J = 8.7 Hz, 2H), 3.90 (s, 2H), 3.85 (s, 3H), 3.81 (s, 3H), 3.63 (s, 3H). 13C NMR (75 
MHz, CDCl3) δ (ppm): 194.2, 190.8, 161.4 (d, J = 244.1 Hz), 160.2, 159.8, 155.9, 155.2, 
152.6, 146.2, 138.3, 137.1, 136.0 (d, J = 3.2 Hz), 131.9, 130.3, 130.2, 130.1 (d, J = 7.8 Hz), 
127.9, 126.2, 124.9, 121.2, 120.0, 116.7, 115.2 (d, J = 21.2 Hz), 61.4, 60.7, 35.3. 19F NMR 
(282.4 MHz, CDCl3) δ (ppm): −117.1. HRMS (ESI
+): C30H25FO6Na [M + Na]
+ m/z; calc: 
523.1533, found: 523.1533.  
 
 4.4.8 preparation of 1-(5-(4-fluorobenzyl)-2,3,4-trimethoxyphenyl)-6-
phenoxyphthalazine (12) 
 
To a solution of 11 (116 mg, 0.23 mmol) in EtOH (5 ml) at rt, was added N2H4.H2O (56 µl, 5 
eq.). The mixture was stirred under reflux for 1h and it was concentrated in vacuo. The crude 
product was purified on a silica gel column using a 1/1 mixture of pentane/EA as eluent to 
afford phthalazine 12 (83 mg, 72%) as a colorless viscous oil. 1H NMR (300 MHz, CDCl3) δ 
(ppm): 9.36 (s, 1H), 7.75 (d, J = 9.0 Hz, 1H), 7.54 (dd, J = 2.1,  9.0 Hz, 1H), 7.46 (t, J = 7.9 
Hz, 2H), 7.27 (tt, J = 1.1, 7.4 Hz, 1H), 7.21-7.12 (m, 5H), 6.99 (s, 1H), 6.93 (t, J = 8.7 Hz, 
  
2H), 3.97 (s, 3H), 3.94 (s, 2H), 3.81 (s, 3H), 3.60 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 
(ppm): 161.2 (d, J = 243.8 Hz), 160.8, 154.7, 153.0, 150.7, 146.3, 136.3 (d, J = 3.2 Hz), 
130.5, 130.3, 130.2 (d, J = 7.9 Hz), 129.3, 128.3, 126.4, 125.6, 125.3, 124.8, 122.4, 120.5, 
115.0 (d, J = 21.2 Hz), 109.5, 61.6, 60.8, 60.7, 35.2. 19F NMR (282.4 MHz, CDCl3) δ (ppm): 
−117.4. HRMS (ESI+): C30H25FN2O4Na [M + Na]
+ m/z; calc: 519.1696, found: 519.1693.  
 
 4.4.9 preparation of 4-(4-fluorobenzyl)-6-(6-phenoxyphthalazin-1-yl)benzene-
1,2,3-triol (2) 
 
To a stirred solution of compound 12 (68 mg, 0.14 mmol) was added dropwise BBr3 (1.4 ml, 
10 eq., 1M in CH2Cl2) in CH2Cl2 (5 mL) at -78°C under nitrogen. The reaction mixture was 
allowed to warm up to rt and stirred overnight. The mixture was quenched with MeOH. After 
evaporation of the solvent to dryness, the residue was recrystallized from a 7/3 mixture of 
pentane/CHCl3 to afford 2 (50 mg, 80%) as a yellow solid. MP: 177-179°C (dcp.). 
1H NMR 
(300 MHz, Acetone D6) δ (ppm): 9.71 (s, 1H), 8.48 (d, J = 9.2 Hz, 1H), 8.01 (dd, J = 2.4, 9.2 
Hz, 1H), 7.80 (d, J = 2.4 Hz, 1H), 7.61 (t, J = 7.8 Hz, 2H), 7.43 (tt, J = 1.1, 7.4 Hz, 1H), 7.39-
7.30 (m, 4H), 7.01 (t, J = 8.9 Hz, 2H), 6.95 (s, 1H), 3.97 (s, 2H). 13C NMR (100 MHz, 
Acetone D6) δ (ppm): 167.7, 163.2 (d, J = 241.8 Hz), 159.2, 155.8, 153.3, 151.2, 145.6, 138.9 
(d, J = 3.1 Hz), 135.8, 135.4, 134.3, 132.7, 132.4 (d, J = 7.8 Hz), 129.0, 128.4, 128.4, 125.4, 
125.0, 123.5, 122.9, 116.6 (d, J = 21.2 Hz), 113.2, 36.1. 19F NMR (282.4 MHz, Acetone D6) δ 
(ppm): −119.2. HRMS (ESI+): C27H20FN2O4 [M + H]
+ m/z; calc: 455.1407, found: 455.1405.  
 
4.5 BRET assay:  
For BRET quantification assays, Hela cells were seeded on 6-well plates and transfected with 
pRLuc-Bax coding for BRET donor and peYFP-Bcl-xL coding for BRET acceptor (or with 
pCMV-Bcl-xL for control). A single donor/acceptor ratio (200ng/1000ng) was used to carry 
out the drug treatment assay. Twenty-four hours after transfection, cells were trypsinized and 
re-seeded into white 96 flat well plate, incubated for another day, and then treated with drugs 
for 16 hours at 10µM before measurment. Light emission at 485 nm and 530 nm was 
measured consecutively by using the Mithras fluorescence-luminescence detector LB 940 
(Berthold) after adding the luciferase substrate, coelenterazine H (Uptima) at a final 
concentration of 5 μM. BRET ratios were calculated as described.
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4.6 Immunoprecipitation: 
Mcf7 cells were co-transfected with pCMV-Bcl-xL and pCMV-Bax plasmids, then treated 
overnight with 10 mM of each compound as stated in the figure (9B). Immunoprecipitation 
assays were performed on 500 mg of sonicated PBS-1% CHAPS lysat using Bcl-xL antibody 
(Epitomics) or flag antibody for control I.P.(Sigma). After overnight incubation at 4°C, 
antibodies were captured by A/G mix magnetic beads (Millipore) according to manufacturer's 
instructions. Following denaturing elution, samples were submit to SDS page, blotted, and 
incubated with either Bax antibody (Dako), Actin (Millipore) or the aforementioned Bcl-xL 
antibody. Membranes were eventually revealed using Clean Blot IP detection 
(ThermoScientific). 
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